338 related articles for article (PubMed ID: 28364655)
1. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
Steinhoff BJ; Bacher M; Bucurenciu I; Hillenbrand B; Intravooth T; Kornmeier R; Kurth C; Stockinger J; Staack AM
Seizure; 2017 May; 48():11-14. PubMed ID: 28364655
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
[TBL] [Abstract][Full Text] [Related]
3. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
[TBL] [Abstract][Full Text] [Related]
4. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.
Schubert-Bast S; Willems LM; Kurlemann G; Knake S; Müller-Schlüter K; Rosenow F; Strzelczyk A
Epilepsy Behav; 2018 Dec; 89():89-93. PubMed ID: 30390435
[TBL] [Abstract][Full Text] [Related]
7. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
11. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
Strzelczyk A; Zaveta C; von Podewils F; Möddel G; Langenbruch L; Kovac S; Mann C; Willems LM; Schulz J; Fiedler B; Kurlemann G; Schubert-Bast S; Rosenow F; Beuchat I
Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
[TBL] [Abstract][Full Text] [Related]
14. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
[TBL] [Abstract][Full Text] [Related]
15. Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: A retrospective outcome analysis.
Snoeren A; Majoie MHJM; Fasen KCFM; Ijff DM
Seizure; 2022 Mar; 96():102-107. PubMed ID: 35184005
[TBL] [Abstract][Full Text] [Related]
16. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
Naddell S; Manuel M; Cavill R; White P; Sieradzan K
Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
18. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
Stephen L; Brodie MJ
Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
